{"id":9004111222133236,"date":"2025-08-28T10:32:17","date_gmt":"2025-08-28T09:32:17","guid":{"rendered":"https:\/\/www.hgf.com\/?p=9004111222133236"},"modified":"2026-06-05T14:36:11","modified_gmt":"2026-06-05T13:36:11","slug":"a-leading-case-beware-sequence-errors-in-patent-claims","status":"publish","type":"post","link":"https:\/\/www.hgf.com\/de\/knowledge-hub\/articles\/a-leading-case-beware-sequence-errors-in-patent-claims\/","title":{"rendered":"A leading case – beware sequence errors in patent claims"},"content":{"rendered":"

Samsung Bioepis UK Ltd v Alexion Pharmaceuticals Inc\u00a0[2025] EWHC 1240 (Pat)<\/a> \u2013 Mr Justice Meade – 20 May 2025<\/strong><\/p>\n

The UK Patents Court has held that Samsung Bioepis\u2019 and Amgen\u2019s eculizumab biosimilars for treating PNH did not infringe Alexion\u2019s EP3167888<\/a>, as the claims covered the amino acid sequence of eculizumab including the leader sequence (which is in fact cleaved off during production of the biopharmaceutical product).\u00a0 Importantly, the Defendants\u2019 biosimilars of eculizumab did not comprise this leader sequence. \u00a0These proceedings are a reminder that incorrect amino acid claims can be fatal in infringement proceedings \u2013 even when the commercial product is a blockbuster drug.<\/p>\n

Background<\/strong><\/p>\n

Alexion brought patent infringement actions against Samsung Bioepis (\u201cSB\u201d) and Amgen in May 2024, alleging that their respective biosimilar products infringed the UK patent derived from European Patent No. 3167888B1 (\u201cPatent\u201d).\u00a0 The dispute related to Alexion\u2019s blockbuster recombinant humanised monoclonal antibody Soliris\u00ae (International Non-proprietary Name (\u201cINN\u201d) eculizumab), which is used in the treatment of the rare condition paroxysmal nocturnal haemoglobinuria (\u201cPNH\u201d).<\/p>\n

Eculizumab was originally protected by a patent family having a priority date of 2 May 1994, which provided basis for Alexion to obtain a Supplementary Protection Certificate (\u201cSPC\u201d) that covered eculizumab until 2020. \u00a0This patent family did not specifically disclose the amino acid sequence of eculizumab.<\/p>\n

In 1999, Alexion submitted a sequence of eculizumab to Chemical Abstracts Service (\u201cCAS\u201d) in order to obtain an INN for eculizumab, which was initially published in 2002 and later on in 2003. During this time, clinical work on eculizumab continued. None of the CAS submissions disclosed the specific amino acid sequence of eculizumab.<\/p>\n

Alexion continued to seek patent protection for eculizumab including a PCT filed in March 2007 (WO 2007\/106585<\/a>) (\u201cWO \u2018585\u201d) which covered the use of a compound that inhibits C5b-9 (i.e., eculizumab) to improve the quality of life in a patient with PNH.<\/p>\n

In 2009 Alexion realised the sequence submitted to CAS had an error and re-submitted a corrected sequence. \u00a0Accordingly, the amino acid sequence of eculizumab had not, prior to this 2009 CAS amendment, actually been disclosed. \u00a0In fact, WO \u2018585 was the first disclosure of the correct amino acid sequence of eculizumab.<\/p>\n

As the sequence of eculizumab did not form part of the state of the art at the time of filing WO \u2018585, Alexion was seeking protection for eculizumab as such rather than solely for its medical use.<\/p>\n

However, a further error (separate to the CAS error) emerged. In the WO \u2018585 family, the claimed amino acid sequence (SEQ ID NO: 4) included the eculizumab sequence plus an extra 22 amino acids at the N-terminal (the leader sequence). During protein production typically the leader sequence is cleaved off. Accordingly, eculizumab itself does not in fact comprise this leader sequence. \u00a0Alexion attempted to amend the claims at the EPO so as to not claim the additional 22 amino acids but these amendments were rejected for added matter.<\/p>\n

Claim construction and infringement<\/strong><\/p>\n

Mr Justice Meade agreed with the Defendants\u2019 claim construction:<\/p>\n

(i)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 the language of the claims \u2013 SEQ ID NO: 4 was of scientific language that would generally be expected to be precise and the use of the drafting convention that \u201cconsisting of\u201d specifies exactly what must be present (paragraph [208]); and<\/p>\n

(ii)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 the skilled person would understand that the Patent was trying to claim something new and the \u201cwhole specification reads as if eculizumab was old and what was being contributed was new ways of using it<\/em>\u201d (paragraph [209]). Therefore, the skilled person would not expect the claims to be covering something old, such as eculizumab.<\/p>\n

The Judge was critical of some of Alexion\u2019s arguments, noting that \u201cpatents do sometimes claim things which are suboptimal or whose purpose is not entirely evident\u201d, however he concluded that such circumstances are \u201cnot a licence to rewrite the claims\u201d.\u00a0 Accordingly, Meade J held that the Defendants\u2019 eculizumab biosimilars did not infringe the Patent.\u00a0 It should be noted that neither party sought to argue that the doctrine of equivalents applied.<\/p>\n

Meade J observed that had he agreed with Alexion\u2019s construction of its claims, the Patent would have been held invalid as it was obvious over the prior art.<\/p>\n

Meade J dismissed the Defendants arguments based on the file history. In accordance with Actavis v Eli Lilly,<\/em>[1]<\/a> the Judge noted that that claims were not ambiguous, and even if they were, he could not see how the file could \u201cunambiguously resolve\u201d the point.<\/p>\n

Parallel UPC Proceedings<\/strong><\/p>\n

Alexion had also brought infringement proceedings against the Defendants at the UPC and sought a preliminary injunction on the basis of the Patent. \u00a0The PI was rejected by both the UPC\u2019s Hamburg Local Division and Court of Appeal<\/a> (\u201cUPC CoA\u201d).<\/p>\n

The UPC CoA noted that during prosecution before the EPO\u2019s Technical Boards of Appeal, Alexion had submitted that the antibody with the leader sequence might bind the relevant protein but said that the position had changed in Alexion\u2019s arguments before it.<\/p>\n

The UPC CoA held that the claims were limited to eculizumab with the 22 amino acid leader sequence and were invalid for insufficiency.\u00a0 Although, his Judgment on validity was made on a different basis, Meade J noted that his decision was consistent with that of the CoA on claim construction which \u201cfortified\u201d him in his conclusion, although he also made clear such consistency was not necessary.<\/p>\n

Meade J also observed that although not material to his decision making, that \u201cthe UPC proceedings \u2026 further illustrate[d] Alexion\u2019s ever-changing positions\u201d.<\/p>\n

Conclusion<\/strong><\/p>\n

This Judgment highlights the importance in ensuring the accuracy of sequence information in patent applications and that a simple error in a single sequence has the ability to render a patent covering a blockbuster drug unenforceable.\u00a0 It also confirms that file wrapper estoppel is rarely useful before the UK Patents Court. \u00a0It is interesting to note that, as with judgments of key national patents courts, the UK patent judges are considering substantive parallel judgments from the UPC also.<\/p>\n

This case serves as a reminder that with increased focus on harmonisation in the EPC, running consistent arguments across different European jurisdictions can be important.\u00a0 Here, the patentee\u2019s changing position on key issues was looked at negatively by both the UPC and the UK Patents Court.<\/p>\n

[1]<\/a> Actavis v Eli Lilly <\/em>[2017] UKSC 48 see [228]-[229].<\/p>\n

\n

This article was written by Trainee Patent Attorney Alex Bruce<\/a>, IP Solicitor Sian Hope<\/a>, and Partner & Head of Law Rachel Fetches<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

Samsung Bioepis UK Ltd v Alexion Pharmaceuticals Inc\u00a0[2025] EWHC 1240 (Pat) \u2013 Mr Justice Meade – 20 May 2025 The UK Patents Court has held that Samsung Bioepis\u2019 and Amgen\u2019s …<\/p>\n","protected":false},"author":502,"featured_media":9004111222133237,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[498,497],"tags":[],"class_list":["post-9004111222133236","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-knowledge-hub","service-patents"],"acf":[],"yoast_head":"\nA leading case - beware sequence errors in patent claims - HGF<\/title>\n<meta name=\"description\" content=\"Examining a leading case on sequence errors in patent claims and what it means for patent drafting and legal strategy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hgf.com\/de\/knowledge-hub\/articles\/a-leading-case-beware-sequence-errors-in-patent-claims\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A leading case - beware sequence errors in patent claims\" \/>\n<meta property=\"og:description\" content=\"Samsung Bioepis UK Ltd v Alexion Pharmaceuticals Inc\u00a0 EWHC 1240 (Pat) \u2013 Mr Justice Meade - 20 May 2025 The UK Patents Court has held that Samsung Bioepis\u2019\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hgf.com\/de\/knowledge-hub\/articles\/a-leading-case-beware-sequence-errors-in-patent-claims\/\" \/>\n<meta property=\"og:site_name\" content=\"HGF\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-28T09:32:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-05T13:36:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hgf.com\/wp-content\/uploads\/2025\/08\/Untitled-design-16-1-300x169-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"169\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Georgia Melia\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hgf_ip\" \/>\n<meta name=\"twitter:site\" content=\"@hgf_ip\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Georgia Melia\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/articles\\\/a-leading-case-beware-sequence-errors-in-patent-claims\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/articles\\\/a-leading-case-beware-sequence-errors-in-patent-claims\\\/\"},\"author\":{\"name\":\"Georgia Melia\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#\\\/schema\\\/person\\\/7df0a22a79ff7cc91642cd3ce4882036\"},\"headline\":\"A leading case – beware sequence errors in patent claims\",\"datePublished\":\"2025-08-28T09:32:17+00:00\",\"dateModified\":\"2026-06-05T13:36:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/articles\\\/a-leading-case-beware-sequence-errors-in-patent-claims\\\/\"},\"wordCount\":1055,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/articles\\\/a-leading-case-beware-sequence-errors-in-patent-claims\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/Untitled-design-16-1-300x169-1.png\",\"articleSection\":[\"Articles\",\"Knowledge Hub\"],\"inLanguage\":\"de-DE\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/articles\\\/a-leading-case-beware-sequence-errors-in-patent-claims\\\/\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/articles\\\/a-leading-case-beware-sequence-errors-in-patent-claims\\\/\",\"name\":\"A leading case - beware sequence errors in patent claims - HGF\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/articles\\\/a-leading-case-beware-sequence-errors-in-patent-claims\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/articles\\\/a-leading-case-beware-sequence-errors-in-patent-claims\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/Untitled-design-16-1-300x169-1.png\",\"datePublished\":\"2025-08-28T09:32:17+00:00\",\"dateModified\":\"2026-06-05T13:36:11+00:00\",\"description\":\"Examining a leading case on sequence errors in patent claims and what it means for patent drafting and legal strategy.\",\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/articles\\\/a-leading-case-beware-sequence-errors-in-patent-claims\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/knowledge-hub\\\/articles\\\/a-leading-case-beware-sequence-errors-in-patent-claims\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/Untitled-design-16-1-300x169-1.png\",\"contentUrl\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/Untitled-design-16-1-300x169-1.png\",\"width\":300,\"height\":169},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/\",\"name\":\"HGF\",\"description\":\"Intellectual Property Rights specialists\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#organization\",\"name\":\"HGF\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/hgf-logo-696x696-1.png\",\"contentUrl\":\"https:\\\/\\\/www.hgf.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/hgf-logo-696x696-1.png\",\"width\":696,\"height\":696,\"caption\":\"HGF\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hgf_ip\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hgf-limited-intellectual-property-specialists\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hgf.com\\\/de\\\/#\\\/schema\\\/person\\\/7df0a22a79ff7cc91642cd3ce4882036\",\"name\":\"Georgia Melia\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bc759620959e751b0f1ac49d89cb60b8f62218f980cb9e4919ee6eb01c4fed6f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bc759620959e751b0f1ac49d89cb60b8f62218f980cb9e4919ee6eb01c4fed6f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bc759620959e751b0f1ac49d89cb60b8f62218f980cb9e4919ee6eb01c4fed6f?s=96&d=mm&r=g\",\"caption\":\"Georgia Melia\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"A leading case - beware sequence errors in patent claims - HGF","description":"Examining a leading case on sequence errors in patent claims and what it means for patent drafting and legal strategy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hgf.com\/de\/knowledge-hub\/articles\/a-leading-case-beware-sequence-errors-in-patent-claims\/","og_locale":"de_DE","og_type":"article","og_title":"A leading case - beware sequence errors in patent claims","og_description":"Samsung Bioepis UK Ltd v Alexion Pharmaceuticals Inc\u00a0 EWHC 1240 (Pat) \u2013 Mr Justice Meade - 20 May 2025 The UK Patents Court has held that Samsung Bioepis\u2019","og_url":"https:\/\/www.hgf.com\/de\/knowledge-hub\/articles\/a-leading-case-beware-sequence-errors-in-patent-claims\/","og_site_name":"HGF","article_published_time":"2025-08-28T09:32:17+00:00","article_modified_time":"2026-06-05T13:36:11+00:00","og_image":[{"width":300,"height":169,"url":"https:\/\/www.hgf.com\/wp-content\/uploads\/2025\/08\/Untitled-design-16-1-300x169-1.png","type":"image\/png"}],"author":"Georgia Melia","twitter_card":"summary_large_image","twitter_creator":"@hgf_ip","twitter_site":"@hgf_ip","twitter_misc":{"Verfasst von":"Georgia Melia","Gesch\u00e4tzte Lesezeit":"5 Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/articles\/a-leading-case-beware-sequence-errors-in-patent-claims\/#article","isPartOf":{"@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/articles\/a-leading-case-beware-sequence-errors-in-patent-claims\/"},"author":{"name":"Georgia Melia","@id":"https:\/\/www.hgf.com\/de\/#\/schema\/person\/7df0a22a79ff7cc91642cd3ce4882036"},"headline":"A leading case – beware sequence errors in patent claims","datePublished":"2025-08-28T09:32:17+00:00","dateModified":"2026-06-05T13:36:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/articles\/a-leading-case-beware-sequence-errors-in-patent-claims\/"},"wordCount":1055,"publisher":{"@id":"https:\/\/www.hgf.com\/de\/#organization"},"image":{"@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/articles\/a-leading-case-beware-sequence-errors-in-patent-claims\/#primaryimage"},"thumbnailUrl":"https:\/\/www.hgf.com\/wp-content\/uploads\/2025\/08\/Untitled-design-16-1-300x169-1.png","articleSection":["Articles","Knowledge Hub"],"inLanguage":"de-DE"},{"@type":"WebPage","@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/articles\/a-leading-case-beware-sequence-errors-in-patent-claims\/","url":"https:\/\/www.hgf.com\/de\/knowledge-hub\/articles\/a-leading-case-beware-sequence-errors-in-patent-claims\/","name":"A leading case - beware sequence errors in patent claims - HGF","isPartOf":{"@id":"https:\/\/www.hgf.com\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/articles\/a-leading-case-beware-sequence-errors-in-patent-claims\/#primaryimage"},"image":{"@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/articles\/a-leading-case-beware-sequence-errors-in-patent-claims\/#primaryimage"},"thumbnailUrl":"https:\/\/www.hgf.com\/wp-content\/uploads\/2025\/08\/Untitled-design-16-1-300x169-1.png","datePublished":"2025-08-28T09:32:17+00:00","dateModified":"2026-06-05T13:36:11+00:00","description":"Examining a leading case on sequence errors in patent claims and what it means for patent drafting and legal strategy.","inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hgf.com\/de\/knowledge-hub\/articles\/a-leading-case-beware-sequence-errors-in-patent-claims\/"]}]},{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.hgf.com\/de\/knowledge-hub\/articles\/a-leading-case-beware-sequence-errors-in-patent-claims\/#primaryimage","url":"https:\/\/www.hgf.com\/wp-content\/uploads\/2025\/08\/Untitled-design-16-1-300x169-1.png","contentUrl":"https:\/\/www.hgf.com\/wp-content\/uploads\/2025\/08\/Untitled-design-16-1-300x169-1.png","width":300,"height":169},{"@type":"WebSite","@id":"https:\/\/www.hgf.com\/de\/#website","url":"https:\/\/www.hgf.com\/de\/","name":"HGF","description":"Intellectual Property Rights specialists","publisher":{"@id":"https:\/\/www.hgf.com\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hgf.com\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de-DE"},{"@type":"Organization","@id":"https:\/\/www.hgf.com\/de\/#organization","name":"HGF","url":"https:\/\/www.hgf.com\/de\/","logo":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/www.hgf.com\/de\/#\/schema\/logo\/image\/","url":"https:\/\/www.hgf.com\/wp-content\/uploads\/2023\/04\/hgf-logo-696x696-1.png","contentUrl":"https:\/\/www.hgf.com\/wp-content\/uploads\/2023\/04\/hgf-logo-696x696-1.png","width":696,"height":696,"caption":"HGF"},"image":{"@id":"https:\/\/www.hgf.com\/de\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hgf_ip","https:\/\/www.linkedin.com\/company\/hgf-limited-intellectual-property-specialists\/"]},{"@type":"Person","@id":"https:\/\/www.hgf.com\/de\/#\/schema\/person\/7df0a22a79ff7cc91642cd3ce4882036","name":"Georgia Melia","image":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/secure.gravatar.com\/avatar\/bc759620959e751b0f1ac49d89cb60b8f62218f980cb9e4919ee6eb01c4fed6f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bc759620959e751b0f1ac49d89cb60b8f62218f980cb9e4919ee6eb01c4fed6f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bc759620959e751b0f1ac49d89cb60b8f62218f980cb9e4919ee6eb01c4fed6f?s=96&d=mm&r=g","caption":"Georgia Melia"}}]}},"_links":{"self":[{"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/posts\/9004111222133236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/users\/502"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/comments?post=9004111222133236"}],"version-history":[{"count":0,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/posts\/9004111222133236\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/media\/9004111222133237"}],"wp:attachment":[{"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/media?parent=9004111222133236"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/categories?post=9004111222133236"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hgf.com\/de\/wp-json\/wp\/v2\/tags?post=9004111222133236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}